Selected Publications

Girotti MR, Lopes F, Preece N, Niculescu-Duvaz D, Zambon A, Davies L, Whittaker S, Saturno G, Viros A, Pedersen M, Suijkerbuijk BM, Menard D, McLeary R, Johnson L, Fish L, Ejiama S, Sanchez-Laorden B, Hohloch J, Carragher N, Macleod K, Ashton G, Marusiak AA, Fusi A, Brognard J, Frame M, Lorigan P, Marais R, Springer C. Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma. Cancer Cell. 2015 Jan 12;27(1):85-96.

Smith MP, Sanchez-Laorden B, O'Brien K, Brunton H, Ferguson J, Young H, Dhomen N, Flaherty KT, Frederick DT, Cooper ZA, Wargo JA, Marais R, Wellbrock C. The Immune Microenvironment Confers Resistance to MAPK Pathway Inhibitors through Macrophage-Derived TNFα. Cancer Discov. 2014 Oct;4(10):1214-29.

Girotti MR, Saturno G, Lorigan P, Marais R.No longer an untreatable disease: How targeted and immunotherapies have changed the management of melanoma patients. Mol Oncol. 2014 Sep 12;8(6):1140-1158. Review.

Viros A, Marais R. Hooked on UVR. Pigment Cell Melanoma Res.  2014 Nov;27(6):1009-10.

Pedersen M, Viros A, Cook M, Marais R. G12 D NRAS and kinase-dead BRAF cooperate to drive naevogenesis and melanomagenesis. Pigment Cell Melanoma Res., 2014 Nov;27(6):1162-6.

Viros A, Sanchez-Laorden B, Pedersen M, Furney SJ, Rae J, Hogan K, Ejiama S, Girotti MR, Cook M, Dhomen N, Marais R. Ultraviolet radiation accelerates BRAF-driven melanomagenesis by targeting TP53. Nature. 2014 Jul 24;511(7510):478-82.

Orgaz JL, Pandya P, Dalmeida R, Karagiannis P, Sanchez-Laorden B, Viros A, Albrengues J, Nestle FO, Ridley AJ, Gaggioli C, Marais R, Karagiannis SN, Sanz-Moreno V. Diverse matrix metalloproteinase functions regulate cancer amoeboid migration. Nat Commun. 2014 Jun 25;5:4255

Furney SJ, Turajlic S, Stamp G, Meirion Thomas J, Hayes A, Strauss D, Gavrielides M, Xing W, Gore M, Larkin J, Marais R. The mutational burden of acral melanoma revealed by whole genome sequencing and comparative analysis. Pigment Cell Melanoma Res. 2014 Sep;27(5):835-8.

Marusiak AA, Edwards ZC, Hugo W, Trotter EW, Girotti MR, Stephenson NL, Kong X, Gartside MG, Fawdar S, Hudson A, Breitwieser W, Hayward NK, Marais R, Lo RS, Brognard J. Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitors. Nat Commun. 2014 May 22;5:3901.

Sanchez-Laorden B, Viros A, Girotti MR, Pedersen M, Saturno, G, Zambon A, Niculescu-Duvaz D, Turajlic S, Hayes A, Gore M, Larkin J, Lorigan P, Cook M, Springer C and Marais R. BRAF inhibitors induce metastasis in RAS-mutant and inhibitor-resistant melanoma cells through MEK/ERK pathway reactivation. Science Signaling 2014 7(318), ra30.

Turajlic S, Furney SJ, Stamp G, Rana S, Ricken G, Oduko Y, Saturno G, Springer C, Hayes A, Gore M, Larkin J, Marais R. Whole genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition. Annals of Oncology, 2014 May;25(5):959-67.

Gentien D, Kosmider O, Nguyen-Khac F, Albaud B, Rapinat A, Dumont AG, Damm F, Popova T, Marais R, Fontenay M, Roman-Roman S, Bernard OA, Stern MH. A common alternative splicing signature is associated with SF3B1 mutations in malignancies from different cell lineages. Leukemia, 2014 Jun;28(6):1355-7.

Escuin-Ordinas H, Atefi M, Fu Y, Cass A, Ng C, Huang RR, Yashar S, Comin-Anduix B, Avramis E, Cochran AJ, Marais R, Lo RS, Graeber TG, Herschman HR, Ribas A.  COX-2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors. Molecular Oncology 2014 8(2):250-60.

Furney SJ, Pedersen M, Gentien D, Dumont AG, Rapinat A, Desjardins L, Turajlic S, Piperno-Neumann S, de la Grange P, Roman-Roman S, Stern MH, Marais R. SF3B1 mutations are associated with alternative splicing in uveal melanoma. Cancer Discov. 2013 3(10) 1122-9.

Rebocha AP and Marais R. ARAF acts as a scaffold to stabilize BRAF:CRAF heterodimers.Oncogene 2013 32: 3207-3212.

Martin M, Marais R. Braking BRAF: AMPK Leaves ERK Stranded in the Desert. Mol Cell. 2013 52(2):155-6.

Marais R, Sellers W, Livingston D, Mihich E. Twenty-fourth annual Pezcoller symposium: Molecular basis for resistance to targeted agents. Cancer Res 2013 73 1046-1049.

Zambon A, Niculescu-Duvaz D, Niculescu-Duvaz I, Marais R, Springer CJ.  BRAF as a therapeutic target: a patent review (2006 – 2012). Expert Opin Ther Pat 2013 23(2), 155-64.

Sanchez-Laorden B, Viros A, Marais R. Mind the IQGAP. Cancer Cell. 2013 23(6):715-7.

Girotti MR, Marais R. Deja Vu: EGF receptors drive resistance to BRAF inhibitors. Cancer Discov. 2013 3(5):487-90.

Falck Miniotis M, Arunan V, Eykyn TR, Marais R, Workman P, Leach MO, Beloueche-Babari M. MEK1/2 Inhibition Decreases Lactate in BRAF-Driven Human Cancer Cells. Cancer Res. 2013 73(13):4039-49.

Furney SJ, Turajlic S, Stamp G, Nohadani M, Carlisle A, Thomas JM, Hayes A, Strauss D, Gore M, van den Oord J, Larkin J, Marais R. Genome sequencing of mucosal melanomas reveals that they are driven by distinct mechanisms from cutaneous melanoma. J Pathol. 2013 230(3):261-9.

Niculescu-Duvaz D, Niculescu-Duvaz I, Suijkerbuijk BM, Ménard D, Zambon A, Davies L, Pons JF, Whittaker S, Marais R, Springer CJ. Potent BRAF kinase inhibitors based on 2,4,5-trisubstituted imidazole with naphthyl and benzothiophene 4-substituents. Bioorg Med Chem. 2013  21(5):1284-304.

Pedersen M, Küsters-Vandevelde HV, Viros A, Groenen PJ, Sanchez-Laorden B, Gilhuis JH, van Engen-van Grunsven IA, Renier W, Schieving J, Niculescu-Duvaz I, Springer CJ, Küsters B, Wesseling P, Blokx WA, Marais R. Primary melanoma of the CNS in children is driven by congenital expression of oncogenic NRAS in melanocytes. Cancer Discov. 2013 3(4):458-69.

Smith MP, Ferguson J, Arozarena I, Hayward R, Marais R, Chapman A, Hurlstone A, Wellbrock C. Effect of SMURF2 targeting on susceptibility to MEK inhibitors in melanoma. J Natl Cancer Inst. 2013 105(1):33-46.

Girotti MR, Pedersen M, Sanchez-Laorden B, Viros A, Turajlic S, Niculescu-Duvaz D, Zambon A, Sinclair J, Hayes A, Gore M, Lorigan P, Springer C, Larkin J, Jorgensen C, Marais R. Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Cancer Discov. 2013 3(2):158-67

Maertens O, Johnson B, Hollstein P, Frederick DT, Cooper ZA, Messiaen L, Bronson RT, McMahon M, Granter S, Flaherty K, Wargo JA, Marais R, Cichowski K. Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov. 2013 3(3):338-49.

Viros A, Hayward R, Martin M, Yashar S, Yu CC, Shanchez-Laorden B, Zambon A, Niculescu-Duvaz D, Springer C, Lo RS and Marais R. Topical 5-fluorouracil elicits regressions of BRAF inhibitor-induced cutaneous squamous cell carcinoma. Journal of Investigative Dermatology 2013 133(1):274-6.

Andreadi C, Cheung LK, Giblett S, Patel B, Jin H, Mercer K, Kamata T, Lee P, Williams A, McMahon M, Marais R and Pritchard C. (2012). The intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway. Genes & Development, 26: 1945-58.

Martin M and Marais R. (2012). Metformin: A Diabetes Drug for Cancer, or a Cancer Drug for Diabetics? Journal of Clinical Oncology, 30: 2698-2700.

Furney SJ, Turajlic S, Fenwick K, Lambros MB, MacKay A, Ricken G, Mitsopoulos C, Kozarewa I, Hakas J, Zvelebil M, Lord CJ, Ashworth A, Reis-Filho JS, Herlyn M, Murata H and Marais R (2012). Genomic Characterisation of Acral Melanoma Cell Lines. Pigment Cell and Melanoma Research, 25: 488-492.

Cho K-J, Kasai RS, Park J-H, Chigurupati S, Heidorn SJ, van der Hoeven D, Plowman SJ, Kusumi A, Marais R, and Hancock JF. (2012). Raf Inhibitors Target Ras Spatiotemporal Dynamics. Current Biology, 22: 945-955.

Natrajan R, Mackay A, Lambros MB, Weigelt B, Wilkerson PM, Manie E, Grigoriadis A, A’Hern F, van der Groep P, Kozarewa I, Popova T, Mariani O, Turaljic S, Furney SJ, Marais R, Rodruigues DN, Flora AC, Wai P, Pawar V, McDade S, Carroll J, Stoppa-Lyonnet C, Green AR, Ellis IO, Swanton C, van Diest P, Delattre O, Lord CJ, Foulkes WD, Vincent-Salomon A, Ashworth A, Stern MH, and Reis-Filho JS. (2012). A whole-genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor-negative and -positive breast cancers. Journal of Pathology, 227: 29-41.

Martin MJ, Hayward R, Viros A and Marais R. (2012). Metformin Accelerates the Growth of BRAFV600E-Driven Melanoma by Upregulating VEGF-A. Cancer Discover, 2: 344-355.

Rae J, Viros A, Hayward R, Bennett D, Dhomen N, Reis-Filho JS and Marais R. (2012). V600EBraf::Tyr-CreERT2::K14-Kitl mice do not develop superficial spreading-like melanoma: keratinocyte Kit ligand is insufficient to "translocate" V600EBraf-driven melanoma to the epidermis. Journal of Investigative Dermatology, 132: 488-491.

Turajlic S, Furney SJ, Lambros MB, Mitsopoulos C, Kozarewa I, Geyer FC, MacKay A, Hakas J, Zvelebil M, Lord C, Ashworth A, Thomas M, Stamp G, Larkin J, Reis-Filho JS and Marais R. (2012). Whole genome sequencing of matched primary and metastatic acral melanomas. Genome Research, 22: 196-207.

Su F, Viros A, Milagre C, Trunzer K, Bollag C, Spleiss O, Reis-Filho JS, Kong X, Koya RC, Flaherty KT, Chapman PB, Jung Kim M, Hayward F, Martin M, Yang H, Wang Q, Hilton H, Hang JS, Noe J, Lambros M, Geyer F, Dhomen N, Niculescu-Duvaz I, Zambon A, Niculescu-Duvaz D, Preece N, Robert L, Otte NJ, Mok S, Kee D, Ma Y, Zhang C, Habets G, Burton EA, Wong B, Nguyen H, Kockx M, Andries L, Lestini B, Nolop KB, Lee RJ, Joe AK, Troy JL, Gonzalez F, Hutson TE, Puzanov I, Chmielowski B, Springer CJ, McArthur GA, Sosman JA, Lo RS, Ribas A and Marais R.(2012). RAS mutations in cutaneous squamous cell carcinomas with BRAF inhibitors. The New England Journal of Medicine, 366: 207-215.

Packer LM, Rana S, Hayward R, O’Hare T, Eide CA, Rebocho A, Heidorn S, Zabriskie MS, Niculescu-DuvazI, Druker BJ, Springer C and MaraisR. (2011). Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia. Cancer Cell, 20: 715-727.

Sanz-Moreno V, Gaggioli C, Yeo M, Albrengues J, Wallberg F, Viros A, Hooper S, Mitter R, Féral CC, Cook M, Larkin J, Marais R, Meneguzzi G, Sahai E and Marshall C. (2011). ROCK and JAK1 signalling cooperate to control actomyosin contractility in tumor cells and stroma. Cancer Cell, 20: 229-245.

Ahmed M, Barbachano Y, Riddell AM, Hickey J, Newbold KL, Viros A, Harrington KJ, Marais R and Nutting CM. (2011). Analysis of the efficacy and toxicity of sorafenib in thyroid cancer – a phase II study in a UK based population. European Journal of Endocrinology, 165: 315-322.

Soo JK, Mackenzie Ross AD, Kallenberg DM, Milagre C, Heung Chong W, Chow J, Hill L, Hoare S, Collinson RS, Hossain M, Nicol Keith W, Marais R and Bennett DC. (2011). Malignancy without immortality? Evidence for cellular immortalization as a late event in melanoma progression. Pigment Cell and Melanoma Research, 24: 490-503.

Franco AT, Malaguarnera R, Refetoff S, Liao X-H, Lundsmith E, Kimura S, Pritchard C, Marais R, Davies T, Weinstein LS, Chen M, Rosen N, Ghossein R, Knauf JA and Fagin JA. (2011). Thyrotrophin receptor signaling-dependence of Braf-induced thyroid tumor initiation in mice. Proceedings of the National Academy of Sciences USA, 108: 1615-1620.

Arozarena I, Sanchez-Laorden B, Packer L,, Hidalgo-Carcedo C, Hayward R, Viros A, Sahai E and Marais R. (2011). Oncogenic BRAF induces melanoma cell invasion by down-regulating the cGMP-specific phosphodiesterase PDE5A. Cancer Cell, 19: 45-57.

Carragher LAS, Snell KR, Giblett SM, Aldridge VSS, Patel B, Cook SJ, Winton DJ, Marais R and Pritchard CA. (2010). V600EBraf induces gastrointestinal crypt senescence and promotes tumour progression through enhanced CpG methylation of p16INK4a. EMBO Molecular Medicine, 2: 458-471.

Kamata T, Hussain J, Giblett S, Hayward R, Marais R and Pritchard C. (2010). Braf Inactivation drives aneuploidy by deregulation of Craf. Cancer Research, 70: 8475-8486.

Whittaker S, Marais R and Zhu A X. (2010). The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene, 29: 4989–5005.

Dhomen N, Da Rocha Dias S, Hayward R, Ogilvie L, Hedley D, Delmas V, McCarthy A, Henderson D, Springer CJ, Pritchard C, Larue L and Marais R. (2010). Inducible expression of (V600E) Braf using tyrosinase-driven Cre recombinase results in embryonic lethality. Pigment Cell Melanoma Research, 23: 112-120.

Whittaker S, Kirk R, Hayward R, Zambon A,Viros A, Cantarino N, Affolter A, Nourry A, Niculescu-Duvaz D, Springer C and Marais R. (2010). Gatekeeper mutations mediate resistance to BRAF targeted therapies. Science Translational Medicine, 2: 35ra41.

Milagre C, Dhomen N, Geyer FC, Hayward R, Lambros M, Reis-Filho JS and Marais R. (2010). A mouse model of melanoma driven by oncogenic KRAS. Cancer Research, 70: 5549-5557.

Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, Hussain J, Reis-Filho JS, Springer CJ, Pritchard C and Marais R. (2010). Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell, 140: 209-221.

Packer LM, East P, Reis-Filho JS and Marais R. (2009). Identification of direct transcriptional targets of V600EBRAF/MEK signalling in melanoma. Pigment Cell and Melanoma Research, 22: 785-798.

Pinner S, Jordan P, Sharrock K, Bazley L, Collinson L, Marais R, Bonvin E, Goding C and Sahai E. (2009). Intravital imaging reveals transient changes in pigment production and Brn2 exprssion during metastatic melanoma dissemination. Cancer Research, 69: 7969-7977.

Dhomen N, Marais R. (2009). BRAF signaling and targeted therapies in melanoma. Hematology/oncology Clinics of North America, 23: 529-545.

Dhomen N, Reis-Filho JS, Da Rocha Dias S, Hayward R, Savage K, Delmas V, Larue L, Pritchard C and Marais R. (2009). Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell, 15: 294-303.

Niculescu-Duvaz D, Gaulon C, Dijkstra HP, Niculescu-Duvaz I, Zambon A, Ménard D Suijkerbuijk BMJM, Nourry A,Davies L, Manne H, Friedlos F, Ogilvie L, Hedley D, Whittaker S,Kirk R, Gill A, Taylor RD, Raynaud FI, Moreno-Farre J, Marais R and Springer CJ. (2009). Pyridoimidazolones as novel potent inhibitors of V-RAF murine sarcoma viral oncogene homolog B1 (BRAF). Journal of Medicinal Chemistry, 52: 2255-2264.

Casar B, Arozarena I, Sanz-Moreno V, Pinto A, Agudo-Ibáñez L, Marais R, Lewis RE, Berciano MT and Crespo P. (2009). Ras subcellular localization defines extracellular signal-regulated kinase 1 and 2 substrate specificity through distinct utilization of scaffold proteins. Molecular and Cellular Biology, 29: 1338-1353.

Noble C, Mercer K, Hussain J, Carragher L, Giblett S, Hayward R, Patterson C, Marais R and Pritchard C. (2008). CRAF autophosphorylation of serine 621 is required to prevent its proteasome-mediated degradation. Molecular Cell, 31: 862-872.

Wellbrock C, Rana S, Paterson H, Pickersgill H, Brummelkamp T and Marais R. (2008). Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF. PLoS ONE, 3: e2734.

Banerji U, Affolter A, Judson I, Marais R and Workman P. (2008). BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors. Molecular Cancer Therapeutics 7: 737-739.